Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04497779 · ClinicalTrials.gov registry record
Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma
A clinical trial of Symptomatic COVID-19 Infection Laboratory-Confirmed and Asymptomatic COVID-19 Infection Laboratory-Confirmed, sponsored by City of Hope Medical Center.
- Active
- Registry status
- 95
- Enrollment target
- 1
- Study location
NCT04497779: Active study of Symptomatic COVID-19 Infection Laboratory-Confirmed and Asymptomatic COVID-19 Infection Laboratory-Confirmed, sponsored by City of Hope Medical Center.
NCT04497779 is a study of Symptomatic COVID-19 Infection Laboratory-Confirmed and Asymptomatic COVID-19 Infection Laboratory-Confirmed that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 95 participants, above the 37-participant average among 3 other Symptomatic COVID-19 Infection Laboratory-Confirmed trials with a reported enrollment target (157% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04497779, a study of Symptomatic COVID-19 Infection Laboratory-Confirmed and Asymptomatic COVID-19 Infection Laboratory-Confirmed, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- 95 participants
- Enrollment target
- 1
- Study location
Study Summary
Plasma from patients who have recovered from coronavirus disease 2019 (COVID-19) is referred to as COVID-19 convalescent plasma (CCP), and may contain antibodies against SARS-CoV-2, the virus responsible for COVID-19. CCP infusion is being evaluated as a therapeutic or prophylactic approach in COVID-19 patients. The goal of this study is to help develop a bank of convalescent plasma in California, especially in medically underserved communities particularly affected by the disease. In parallel, CCP administered to COVID-19 patients will be collected and analyzed to determine whether the antibody profile correlates with clinical outcome. The purpose of this non-therapeutic study is to learn more about the CCP antibody profile and the effect it may have in treating COVID-19 infection.
Primary Outcome
Will be assayed for severe acute respiratory syndrome (SARS-CoV-2) immunoassay, coronavirus (CoV) PepSeq assay, and SARS-CoV-2 lenti-based neutralizing antibody titer.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Questionnaire Administration
- OTHER Electronic Health Record Review
- OTHER Diagnostic Laboratory Biomarker Analysis
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2020-07-13 |
| Est. Completion | 2026-10-13 |
What the registry record for NCT04497779 still lists
NCT04497779 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 95 participants, a relatively small participant target, above the 37-participant average among 3 other Symptomatic COVID-19 Infection Laboratory-Confirmed trials with a reported enrollment target (157% higher).
The record links to 2 conditions, with Symptomatic COVID-19 Infection Laboratory-Confirmed appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT04497779 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04497779 about?
NCT04497779 is a clinical study titled "Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma". Plasma from patients who have recovered from coronavirus disease 2019 (COVID-19) is referred to as COVID-19 convalescent plasma (CCP), and may contain antibodies against SARS-CoV-2, the virus responsible for COVID-19. CCP infusion is being evaluated as a therapeutic or prophylactic approach in COVID...
What is the current status of trial NCT04497779?
This trial is currently active not recruiting. The enrollment target is 95 participants. The study started on 2020-07-13. Estimated completion is 2026-10-13.
What conditions does trial NCT04497779 study?
This clinical trial studies the following conditions: Symptomatic COVID-19 Infection Laboratory-Confirmed, Asymptomatic COVID-19 Infection Laboratory-Confirmed.
What interventions are being tested in trial NCT04497779?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Questionnaire Administration (OTHER), Electronic Health Record Review (OTHER), Diagnostic Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT04497779?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04497779 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Symptomatic COVID-19 Infection Laboratory-Confirmed
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
RECRUITING · Phase 1
-
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
RECRUITING · Phase 1
-
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI